Average Sales Prices Expected To Increase 3.4% From Proposed Rule
Executive Summary
The Centers for Medicare & Medicaid Services expects that first quarter 2005 reimbursement rates for Medicare Part B drugs will reflect an increase of about 3.4% from those published in its proposed rule
You may also be interested in...
CMS Updates 2005 Part B Payment Rates; Gemzar ASP Increases By 7.3%
Lilly has reversed a 7% price cut for the oncologic Gemzar ahead of the 2005 transition to average sales price-based reimbursement under Medicare Part B
CMS Updates 2005 Part B Payment Rates; Gemzar ASP Increases By 7.3%
Lilly has reversed a 7% price cut for the oncologic Gemzar ahead of the 2005 transition to average sales price-based reimbursement under Medicare Part B
Procrit, Camptosar At Risk Under 2005 Medicare Payment Rates, ASCO Says
Medicare reimbursement rates for 2005 will not cover costs of Johnson & Johnson's Procrit (epoetin) for the majority of oncology practices, according to the American Society of Clinical Oncology